Business Wire

Global Tech and Durables Market in Recovery Mode

3.9.2024 16:00:00 EEST | Business Wire | Press release

Share

2024 looks like a better year than 2023 for the global Consumer Tech and Durables (T&D) market. Inflation rates are easing, consumer confidence is rising, summer bookings are returning to pre-pandemic levels, and major sporting events such as the Paris Olympics and the European Football Championship in Germany are triggering demand.

At the mid-year point, most T&D segments are showing steady growth, and the market overall is slowly recovering, albeit still in negative territory. From January to June 2024, the global T&D market recorded a slight decrease in revenue of minus 0.6 percent to 395 billion US-dollars compared to the same period last year, and NIQ-GfK experts are forecasting that the trend will continue, with stable revenue of minus 0.1 percent for the full year 2024.

Omnichannel remains king

Inflation and high prices continue to be a top concern of consumers worldwide (GfK Consumer Life study), and 57 percent of global consumers are prepared to switch stores to manage costs (NIQ Consumer Outlook report 2024).

“Omnichannel retailing remains popular, with 36 percent of total global T&D sales made online in the first half of 2024 – an increase of 0.4 percent from last year. But consumer behavior is changing, driven by price concerns and a desire for best value for money. The global T&D market must keep pace to achieve long-term, sustainable growth,” explains Nevin Francis, GfK's insights expert for the Tech and Durables industry.

The progress of Chinese online retailers in Europe is quite notable. In the first half of 2024, the Chinese e-commerce retailer, Temu, ranked second in terms of order volume for computers and electronics, although its average order value is lower due to the smaller-ticket price of items. According to Foxintelligence by NielsenIQ, 77 percent of German Temu shoppers in the last 60 days were repeat buyers.

Looking at regional differences, consumer spending caution varies depending on purchasing power and local price levels. While Western Europe and Developed Asia experienced year-on-year revenue declines in the first half of the year (1 percent and 9 percent respectively), Eastern Europe (plus 4 percent) and the Middle East (plus 8 percent) grew, and Emerging Asia also returned to growth.

“Price-conscious consumers are increasingly looking for value for money. As a result, the 15 promotional weeks in a year, such as the mid-year promotion and Black Friday already account for 34 percent of annual T&D revenue,” summarizes Nevin Francis. “Retailers and manufacturers must balance the demand for premiumization with a good price-performance ratio, while focusing on their unique selling proposition. To find that sweet spot, they need to know their target group better than ever before.”

Specific trends driving the half-year results for global T&D

GfK panel data shows that the Telecom and Photo categories are back in the black in the first half of 2024, while other T&D categories regaining momentum and starting to recover:

  • Consumer Electronics (TVs, soundbars, etc.): minus 2 percent
  • Telecom (Smartphones, etc.): plus 2 percent
  • IT (Mobile PCs, hardware, etc.): minus 5 percent
  • Small Domestic Appliances (Fryers, mixers, etc.): minus 1 percent
  • Major Domestic Appliances (ACs, ovens, etc.): minus 2 percent 

Growth in the homeappliances sector is being driven by three key consumer desires: sustainability, simplification and AI-powered intelligence. As personalized features and AI assistants make everyday household tasks more efficient and easier, demand for related devices such as smart ovens and cookers (up 30 percent year-over-year in revenue January 2024 - June 2024) has noticeably increased. In general, convenience-oriented appliances such as robot vacuum cleaners and fully automatic espresso machines (up 9 percent and 7 percent respectively) and more environmentally friendly products such as A-labelled washing machines (up 39 percent in Europe) have gained ground.

In the IT sector, on the other hand, it is still all about premiumization, especially more memory in devices. In laptops, 16GB RAM is becoming the new standard, with sales volume up 3 percent in the first half of 2024 compared to the same period last year, replacing older models. The same is true for media tablets, where 8GB RAM devices with larger displays of 9 inches and above dominate with an impressive 58 percent volume growth rate. In addition, consumers are upgrading their IT accessories, such as Bluetooth keyboards (up 18 percent) and monitors with refresh rates above 240 Hz (up 90 percent).

In contrast to the B2C market, which is slowly recovering, the B2B market is still stuck in the red, according to GfK's distribution panel, with revenues down 6 percent year-on-year in the first half of 2024. Despite this downturn, there are positive signals in certain areas of the mass market. For example, processors (up 4 percent) are growing year-over-year in the first half of 2024. In addition, demand for software was up 8 percent, driven by an increased focus on security and collaboration solutions in the business sector. A standout success in the B2B market is AR/VR glasses, which – although still a niche category – achieved impressive growth of 80 percent, driven mainly by successful product launches beginning of the year.

About the method

Through its retail panels, GfK regularly collects POS (point of sales) data in more than 70 countries worldwide for the consumer electronics, photography, telecommunications, information technology, office equipment, and small and large household appliances sectors. All figures are according to GfK panel market, with global data excluding North America and presented in US dollars NSP (non-subsides price), except stated otherwise.

GfK – a NielsenIQ company

For 90 years, we have earned the trust of our clients around the world by solving critical questions in their decision-making process. We fuel their growth by providing a complete understanding of their consumers’ buying behavior, and the dynamics impacting their markets, brands and media trends. In 2023, GfK combined with NielsenIQ, bringing together two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights - delivered with advanced analytics through state-of-the-art platforms - GfK drives “Growth from Knowledge”.

For more information, visit GfK.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240903945066/en/

Contacts

Eva Böhm
Public Relations
T +49 911 395 4440
Public.relations@smb.nielseniq.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release

inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 15:50:00 EEST | Press release

Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye